ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1933

Incidence and Early Detection of Retinal Toxicity in Patients Treated with Chloroquine and Hydroxichloroquine in Rheumatology Practice

Sandra Soro Marin1, Ana del Carmen Haro Martínez1, Deseada Palma Sanchez1, María del Rocío Gonzalez Molina1, Marta Mayor Gonzalez2 and Elena Rubio Velazquez3, 1Rheumatology, Rafael Mendez Hospital, Spain., Lorca (Murcia), Spain, 2Rheumatology, Rafael Mendez Hospital, Lorca (Murcia), Spain, 3Ophthalmology, Rafael Mendez Hospital, Lorca (Murcia)

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Hydroxychloroquine

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: The antimalarial drugs are considered safe and well tolerated, with low risk of side effects. Hydroxychloroquine is considered safer but less effective than chloroquine, although the choice remains a matter of discussion and it generally depends on the experience. Both can cause ocular toxicity by corneal and retinal deposition which produces irreversible visual disturbances and the patient may not perceive its presence at an early stage. The American Academy of Ophthalmology recommendations for screening of chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy recommend to use more sensitive test than fundus exam such as Spectral Domain Optical Coherence Tomography (SD-OCT) to detect early retinal toxicity. The objective was to study the incidence of retinal toxicity in patients treated with

antimalarials in a Rheumatology Unit and to evaluate the effectiveness of  SD-OCT in the screening  of hydroxichloroquine and chloroquine toxicity

Methods: Descriptive study evaluating 39 patients treated with antimalarials who were referred to ophthalmology to study retinal toxicity during 2011. Data collection included demographic data of patients, type of antimalarial prescribed, daily and cumulative doses, rheumatic disease, corticosteroid use, associated morbidity, visual acuity, examination of the anterior pole, fundus exam, visual field, SD-OCT and, in case that it shows any sign of toxicity, multifocal electroretinogram. Fluorescein angiography (FAG) was made to patients that showed macular disturbances.

Results: Three patients were treated with CQ and 36 with HCQ. Five of 39 patients had alterations in the SD-OCT, two of them had typical fundus appearance and three didn’t show significant changes in visual acuity or retinal imaging. Visual field and electroretinogram helped to confirm early toxicity. Among the patients with retinopathy, three (100%) had been treated with CQ and two (5.5%) with HCQ. The average duration of treatment in these patients was 2.37 + / -1.37 years and the mean cumulative dose of CQ was 559 g and 172.5 g for HCQ. There was no statistically significant association between retinal toxicity and sex, age, rheumatic disease, duration or dose of treatment with p value greater than 0.05.

Conclusion: The incidence of retinal toxicity in our patients treated with antimalarial drugs was 12.8%. Despite the small sample size to prove statistical significance, CQ was the antimalarial that caused most of cases of retinopathy and the SD-OCT was the most sensitive test to detect it. It is essential a fluent communication between Rheumatology and Ophthalmology to have a proper follow-up of the patients treated with CQ and HCQ and an early detection of retinopathy.


Disclosure:

S. Soro Marin,
None;

A. D. C. Haro Martínez,
None;

D. Palma Sanchez,
None;

M. D. R. Gonzalez Molina,
None;

M. Mayor Gonzalez,
None;

E. Rubio Velazquez,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-and-early-detection-of-retinal-toxicity-in-patients-treated-with-chloroquine-and-hydroxichloroquine-in-rheumatology-practice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology